It is therefore important that patients with very early breast/ovarian cancer and congenital abnormalities, as well as patients with an FA-like phenotype (particularly in the absence of BMF), are screened for biallelic BRCA1 mutations. This evidence concerns the gene BRCA1 and ovarian cancer.